It points toward a broader future where metabolism, immunology and neurology may converge in the next generation of therapies
Nikolic, M
R., Gerrish, C., Auh, C.-K
Hers: Key Differences Medications Both platforms offer compounded semaglutide and compounded tirzepatide, along with brand-name options like Ozempic, Wegovy, and Zepbound
Patients who have been on Wegovy or Zepbound through the program would face three options: Pay out of pocket at retail prices (currently $1,000-$1,300 per month) Discontinue the medication , which research suggests leads to significant weight regain Transition to an alternative covered treatment , such as bariatric surgery or other covered medications The STEP 1 extension study showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year
To reach the $100 000/QALY threshold, the current net prices would need to be reduced by 30.5% for tirzepatide and 81.9% for semaglutide
